Where have all the T cells gone? Mechanisms of immune evasion by tumors - PubMed (original) (raw)

Where have all the T cells gone? Mechanisms of immune evasion by tumors

J Finke et al. Immunol Today. 1999 Apr.

No abstract available

PubMed Disclaimer

Similar articles

• Editorial: γδ T Cells in Cancer.
  Coffelt SB, Kabelitz D, Silva-Santos B, Kuball J, Born W, Bank I. Coffelt SB, et al. Front Immunol. 2020 Nov 20;11:602411. doi: 10.3389/fimmu.2020.602411. eCollection 2020. Front Immunol. 2020. PMID: 33329597 Free PMC article. No abstract available.
• Strategies for immunotherapy of cancer.
  Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Melief CJ, et al. Adv Immunol. 2000;75:235-82. doi: 10.1016/s0065-2776(00)75006-1. Adv Immunol. 2000. PMID: 10879286 Review. No abstract available.
• γδ T cells in cancer immunotherapy.
  Zou C, Zhao P, Xiao Z, Han X, Fu F, Fu L. Zou C, et al. Oncotarget. 2017 Jan 31;8(5):8900-8909. doi: 10.18632/oncotarget.13051. Oncotarget. 2017. PMID: 27823972 Free PMC article. Review.
• Cancer immunotherapy: a treatment for the masses.
  Blattman JN, Greenberg PD. Blattman JN, et al. Science. 2004 Jul 9;305(5681):200-5. doi: 10.1126/science.1100369. Science. 2004. PMID: 15247469 Review.
• Adoptive cell therapy: Honing that killer instinct.
  Humphries C. Humphries C. Nature. 2013 Dec 19;504(7480):S13-5. doi: 10.1038/504S13a. Nature. 2013. PMID: 24352359 No abstract available.

Cited by

• The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy.
  Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. Yang Q, et al. Acta Pharm Sin B. 2020 Nov;10(11):2156-2170. doi: 10.1016/j.apsb.2020.04.004. Epub 2020 Apr 19. Acta Pharm Sin B. 2020. PMID: 33304783 Free PMC article. Review.
• Contemporary treatment of metastatic renal cell carcinoma.
  Wiechno P, Kucharz J, Sadowska M, Michalski W, Sikora-Kupis B, Jonska-Gmyrek J, Poniatowska G, Nietupski K, Ossolinski K, Demkow T. Wiechno P, et al. Med Oncol. 2018 Oct 27;35(12):156. doi: 10.1007/s12032-018-1217-1. Med Oncol. 2018. PMID: 30368624 Review.
• Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy.
  Aparicio LMA, Fernandez IP, Cassinello J. Aparicio LMA, et al. Clin Transl Oncol. 2017 Oct;19(10):1175-1182. doi: 10.1007/s12094-017-1657-7. Epub 2017 Apr 13. Clin Transl Oncol. 2017. PMID: 28409322 Free PMC article. Review.
• Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma.
  Cai C, Zhang J, Li M, Wu ZJ, Song KH, Zhan TW, Wang LH, Sun YH. Cai C, et al. Tumour Biol. 2016 Jun;37(6):8209-18. doi: 10.1007/s13277-015-4687-1. Epub 2015 Dec 30. Tumour Biol. 2016. PMID: 26715281
• GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway.
  Mahata B, Biswas S, Rayman P, Chahlavi A, Ko J, Bhattacharjee A, Li YT, Li Y, Das T, Sa G, Raychaudhuri B, Vogelbaum MA, Tannenbaum C, Finke JH, Biswas K. Mahata B, et al. PLoS One. 2015 Jul 30;10(7):e0134425. doi: 10.1371/journal.pone.0134425. eCollection 2015. PLoS One. 2015. PMID: 26226135 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database